ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Depreciation & Amortization history
Currency unavailable · from the cash flow
No Depreciation & Amortization data reported for this period type.
Depreciation & Amortization vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.32M USD | +126.8% | +13.8% | 35.5% | |
| LTM Mar 2026 | $8.15M USD | -5.8% | -4.3% | 11.4% | |
| LTM Mar 2026 | $5.7M USD | -10.2% | +34.3% | 141.4% | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $2.28M USD | +9.0% | +4.6% | 7.1% | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $475K USD | +28.7% | +0.3% | — | |
| FY2025 | $323K USD | — | — | 1.7% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -0.9% | +2.8% | 15.8% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.